FDA OKs Extended-Release Amantadine (Osmolex ER) for Parkinson's FDA OKs Extended-Release Amantadine (Osmolex ER) for Parkinson's
Osmolex ER tablets, taken once daily in the morning, are a proprietary formulation containing immediate- and extended-release amantadine.FDA Approvals
Conclusion: In idiopathic PD with MCI, atomoxetine does not improve complex attention. Also, a deteriorative trend in the executive function was noted. PMID: 32211146 [PubMed]
Authors: Tatullo M, Marrelli B, Zullo MJ, Codispoti B, Paduano F, Benincasa C, Fortunato F, Scacco S, Zavan B, Cocco T Abstract The scientific community continuously strives to get new disease models, to discover early markers or novel therapeutic approaches, improving the diagnosis and prognosis of several human pathologies. Parkinson's Disease (PD) is characterized by a long asymptomatic phase, characterized by a selective loss of dopaminergic neurons. Recently, the human Periapical Cyst-Mesenchymal Stem Cells (hPCy-MSCs) have been differentiated in functional dopaminergic neurons: such oral-derived MSCs and the ...
Publication date: Available online 27 March 2020Source: NeuroImage: ClinicalAuthor(s): Stefan Lang, Eun Jin Yoon, Mekale Kibreab, Iris Kathol, Jenelle Cheetham, Tracy Hammer, Justyna Sarna, Zahinoor Ismail, Oury Monchi
Authors: Liu H, Liu M, Zhang S, Li W, Wang A, Yang F, Jiang H PMID: 32208409 [PubMed - as supplied by publisher]
(Hokkaido University) A new technique allows researchers to test how the deformation of tiny train track-like cell proteins affects their function. The findings could help clarify the roles of deformed 'microtubules' in traumatic brain injuries and in neurological diseases like Parkinson's.
l-dopa-carbidopa intestinal gel (LCIG) is a validated method of optimizing levodopa (LD) administration in advanced Parkinson's disease (PD).
In conclusion, reduced DJ-1 expression promotes inflammation and IEC apoptosis via p53 in colitis, suggesting that the modulation of DJ-1 expression may be a potential therapeutic strategy for managing colitis.
We describe a 15-year old female adolescent with 22q11.2ds, psychotic disorder, and catatonia. Individuals with 22q11.2ds are at increased risk of developing catatonia. Vulnerability for developing extrapyramidal symptoms and epileptic seizures may complicate pharmacological treatment for psychotic episodes. There may be a diagnostic delay of diagnosing Parkinson's disease in patients taking antipsychotics as parkinsonism may be viewed as a side effect. Health professionals working with people with 22q11.2ds should be aware of the increased prevalence of movement disorders and the threshold for referral to 22q11.2ds specia...
Conditions: Parkinson Disease; Speech Disorders Interventions: Behavioral: Speech-in-Noise Treatment Program; Behavioral: Speech-to-Noise Feedback Device Program Sponsor: Lawson Health Research Institute Not yet recruiting
Conditions: Parkinson Disease; Healthy Interventions: Drug: Foliglurax 10 mg (treatment A); Drug: Foliglurax 30 mg (treatment B); Drug: Placebo (treatment C) Sponsor: H. Lundbeck A/S Recruiting